Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-25. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Mexico (south-eastern): Among the ancient Maya, Nicotiana was considered a sacred plant, closely associated with deities of earth and sky, and used for both visionary and therapeutic ends. The contemporary Tzeltal and Tzotzil Maya of Highland Chiapas (Mexico) are bearers of this ethnobotanical inheritance, preserving a rich and varied tradition of Nicotiana use and folklore. The entire tobacco plant is viewed as a primordial medicine and a powerful botanical "helper" or "protector". Depending on the condition to be treated, whole Nicotiana leaves are used alone or in combination with other herbs in the preparation of various medicinal plasters and teas. In its most common form, fresh or green leaves are ground with slaked lime to produce an intoxicating oral snuff that serves as both a protective and therapeutic agent. United States: Extract of N. tabacum is taken orally to treat tiredness, ward off diseases, and quiet fear. Tanzania: Leaves of Nicotiana tabacum are placed in the vagina to stimulate labor. Zimbabwe: Leaves or root of the plant are infused and taken by mouth for asthma and other respiratory problems. Leaves and roots are also rubbed against warts and wounds as ointment.
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic. It is taken by mouth. Common side effects include dizziness and headaches. Serious side effects may include allergic reactions, electrolyte abnormalities, and glaucoma. Use in pregnancy is not recommended. The combination was approved for medical use in the United States in 1998. It is available as a generic medication. In 2021, it was the 224th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
== Metabolism == Lactiplantibacillus plantarum are homofermentative, aerotolerant Gram-positive bacteria that grow at 15 °C (59 °F), but not at 45 °C (113 °F), and produce both enantiomers of lactic acid (D and L). Many lactobacilli including L. plantarum are unusual in that they can respire oxygen and express cytochromes if heme and menaquinone are present in the growth medium. In the absence of heme and menaquinone, oxygen is consumed by NADH-peroxidase with hydrogen peroxide as intermediate and water as end product. The peroxide, it is presumed, acts as a weapon to exclude competing bacteria from the food source. In place of the protective enzyme superoxide dismutase present in almost all other oxygen-tolerant cells, this organism accumulates millimolar quantities of manganese polyphosphate. Manganese is also used by L. plantarum in a pseudo-catalase to lower reactive oxygen levels. Because the chemistry by which manganese complexes protect the cells from oxygen damage is subverted by iron, these cells contain virtually no iron atoms; in contrast, a cell of Escherichia coli of comparable volume contains over one-million iron atoms. Because of this, L. plantarum cannot be used to create active enzymes that require a heme complex, such as true catalases. L. plantarum can also reduce insoluble terminal electron acceptors, such as iron oxides or solid electrodes through extracellular electron transfer when riboflavin and quinone (such as 1 4-dihydroxy-2-naphthoic acid, DHNA) are present. L.
=== Magnetic droplets === The micro-magnetofluidic method is the control of magnetic fluids by an applied magnetic field on a microfluidic platform, offering wireless and programmable control of the magnetic droplets. Hence, the magnetic force can also be used to perform various logical operations, in addition to the hydrodynamic force and the surface tension force. The magnetic field strength, type of the magnetic field (gradient, uniform or rotating), magnetic susceptibility, interfacial tension, flow rates, and flow rate ratios determine the control of the droplets on a micro-magnetofluidic platform. Magnetic droplets, in the context of droplet-based microfluidics, are microliter size droplets that are either composed of ferrofluids or contain some magnetic component that allows for manipulation via an applied magnetic field. Ferrofluids are homogenous mixtures of colloidal solutions of magnetic nanoparticles in a liquid carrier. Two applications of magnetic droplets are the control and manipulation of microfluidic droplets in a microenvironment and the fabrication, transport, and utilization of nanomaterial constructs in the microdroplets. Manipulating magnetic droplets can be used to perform tasks such as arranging droplets into an ordered array for applications in cell culture studies, while the use of magnetic droplets for nanostructure fabrication can be used in drug delivery applications.
=== China === The People's Republic of China defines a VOC as those compounds that have "originated from automobiles, industrial production and civilian use, burning of all types of fuels, storage and transportation of oils, fitment finish, coating for furniture and machines, cooking oil fume and fine particles (PM 2.5)", and similar sources. In July 2018, the State Council released the "Three-Year Action Plan for Winning the Blue Sky Defence War", planning to reduce 2015 VOC emissions 10% by 2020.
Sources: en.wikipedia.org
==== Mayker Filema Duarte elected ==== On Friday, September 20, 2024, Acting Grand Master Mayker Filema Duarte was unanimously elected Grand Master of the Grand Lodge of Cuba, during the regular annual and semiannual sessions of the High Chamber of the Grand Lodge of Cuba. Due to the special nature of the circumstances, Filema Duarte was understood to only have been elected to finish-out the rest of the term that Urquía Carreño would have normally completed until the next scheduled semi-annual meeting of the High Chamber in March, 2025, when the elections for the positions at the Grand Lodge usually occur. Over the next six months, many Cuban Freemasons started to believe that Filema Duarte was simply an extension of the same brand of corruption and government abuse that Urquía Carreño had been. He had also been risen through the ranks under the administration of Urquía Carreño. The fact that the Office of Associations and its director Miriam García publicly gave their support to Filema Duarte raised their suspicions, leading them to suspect that he was yet another government puppet. On March 23, 2025, the High Chamber met for their normal semi-annual session (they meet every September and March), and old business was conducted with Filema Duarte presiding. When it was time for new business to be conducted, one of the Freemasons reminded him about holding elections, at which point Filema Duarte suspended the session of the High Chamber. The election did not occur.
===== Factors ===== Apart from the requirement that candidates are graduates from approved medical programs and, in the case of residency, licensed as medical doctors, there are no specific criteria an employer has to consider in hiring for an internship or residency position. This system for recruiting has been criticized by The Swedish Medical Association for lacking transparency as well as for delaying time to specialist certification of physicians. There are nevertheless factors that most employers will consider, the most important being how long a doctor has been in active practice. After completing nine out of a total of eleven semesters of medical school a student may work as a physician on a temporary basis—e.g. during summer breaks from university. This rule enables medical graduates to start working as physicians upon graduating from university without yet being licensed, as a way of building experience to be able to eventually be hired into an internship. According to a 2017 survey by The Swedish Medical Association, interns in the country as a whole had worked an average of 10.3 months as physicians before starting their internships, ranging from an average of 5.1 months for interns in the Dalarna region to an average of 19.8 months for interns in the Stockholm region.
== Publications == Phil S. Baran has authored and co-authored approximately 300 research publications with an h-index of 133 and over 60,000 citations. His group's research has been published in journals including Science, Nature, Journal of American Chemical Society (JACS), Angewandte Chemie, and Journal of Organic Chemistry (JOC). Baran has authored the digital interactive reference text The Portable Chemist's Consultant: A Survival Guide for Discovery, Process, and Radiolabeling and contributed chapters and forewords to several scientific publications.
One gram of poppy seeds contains up to 33 micrograms of morphine and 14 micrograms of codeine, and the Substance Abuse and Mental Health Services Administration in the United States formerly mandated that all drug screening laboratories use a standard cutoff of 300 nanograms per milliliter in urine samples. A single poppy seed roll (0.76 grams of seeds) usually did not produce a positive drug test, but a positive result was observed from eating two rolls. A slice of poppy seed cake containing nearly five grams of seeds per slice produced positive results for 24 hours. Such results are viewed as false positive indications of drug use and were the basis of a legal defense. On November 30, 1998, the standard cutoff was increased to 2000 nanograms (two micrograms) per milliliter. Confirmation by gas chromatography-mass spectrometry will distinguish amongst opium and variants including poppy seeds, heroin, and morphine and codeine pharmaceuticals by measuring the morphine:codeine ratio and looking for the presence of noscapine and acetylcodeine, the latter of which is only found in illicitly produced heroin, and heroin metabolites such as 6-monoacetylmorphine.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.